Journey Medical (NASDAQ:DERM) vs. Trulieve Cannabis (NYSE:TRLV) Head-To-Head Review

Trulieve Cannabis (NYSE:TRLV – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Profitability

This table compares Trulieve Cannabis and Journey Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trulieve Cannabis -41.22% -0.34% -0.14%
Journey Medical -7.34% -16.15% -5.38%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Trulieve Cannabis and Journey Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trulieve Cannabis 1 1 1 0 2.00
Journey Medical 2 0 2 0 2.00

Trulieve Cannabis presently has a consensus target price of $15.00, indicating a potential upside of 44.86%. Journey Medical has a consensus target price of $13.00, indicating a potential upside of 251.35%. Given Journey Medical’s higher possible upside, analysts plainly believe Journey Medical is more favorable than Trulieve Cannabis.

Institutional and Insider Ownership

7.2% of Journey Medical shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Trulieve Cannabis and Journey Medical”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trulieve Cannabis $1.18 billion 1.69 -$116.38 million $0.20 51.77
Journey Medical $61.86 million 1.69 -$11.43 million ($0.18) -20.56

Journey Medical has lower revenue, but higher earnings than Trulieve Cannabis. Journey Medical is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Journey Medical beats Trulieve Cannabis on 6 of the 11 factors compared between the two stocks.

About Trulieve Cannabis

(Get Free Report)

Trulieve Cannabis Corp. is a U.S. cannabis company that cultivates, processes and sells cannabis products through a vertically integrated business. Its offerings include flower, concentrates, vape products, edibles and other cannabis products, sold under brands such as Trulieve and Modern Flower. Founded in Florida in 2015, the company built its business in that state and expanded into other U.S. markets, including Arizona and Pennsylvania. Its operations and product offerings are shaped by the regulations in each state where it operates.

About Journey Medical

(Get Free Report)

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.

Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.